预约演示

更新于：2025-08-23

Teriparatide(Chengdu Shengnuo)

特立帕肽（圣诺生物）

更新于：2025-08-23

概要

基本信息

药物类型

合成多肽

别名-

靶点

PTH1R

作用方式

激动剂

作用机制

PTH1R激动剂(甲状旁腺激素受体激动剂)

治疗领域-

在研适应症-

非在研适应症-

原研机构

成都圣诺生物制药有限公司

在研机构

成都圣诺生物制药有限公司

非在研机构-

权益机构-

最高研发阶段临床申请

首次获批日期-

最高研发阶段(中国)临床申请

特殊审评-

登录后查看时间轴

关联

100 项与特立帕肽（圣诺生物）相关的临床结果

登录后查看更多信息

100 项与特立帕肽（圣诺生物）相关的转化医学

登录后查看更多信息

100 项与特立帕肽（圣诺生物）相关的专利（医药）

登录后查看更多信息

923

项与特立帕肽（圣诺生物）相关的文献（医药）

2025-12-01·Current Osteoporosis Reports

Changes in Periprosthetic Bone Mineral Density Following Arthroplasty: An In-Depth Review and Current Perspectives

Review

作者: Hou, Yilin ; Liu, Feiyang ; Li, Daizhi ; Zeng, Yi

PURPOSE OF REVIEW:

Arthroplasty (e.g., TKA, UKA, THA) is a gold-standard treatment for end-stage joint diseases, yet it often leads to periprosthetic bone mineral density (BMD) loss, increasing risks of implant loosening and fractures. This review aims to (1) evaluate current methods for measuring periprosthetic BMD, (2) analyze factors contributing to BMD reduction, and (3) discuss pharmacological interventions to mitigate bone loss, thereby improving postoperative outcomes.

RECENT FINDINGS:

Recent studies highlight three primary BMD assessment tools: DEXA (widely used but limited by artifact interference), QCT (3D precision but higher cost/radiation), and HRpQCT (high-resolution yet restricted to peripheral sites). Key contributors to BMD loss include stress shielding, surgical technique, patient-specific factors (e.g., age, osteoporosis), and postoperative management gaps. Pharmacological agents like teriparatide (anabolic), denosumab (anti-resorptive), and TCM (e.g., Epimedium-derived compounds) show efficacy in preserving periprosthetic BMD. Periprosthetic BMD loss remains a critical challenge post-arthroplasty. While current monitoring tools and pharmacological strategies offer promising solutions, limitations in accessibility and standardization persist. Future research should focus on personalized BMD management protocols, cost-effective monitoring technologies, and long-term outcomes of combined therapies to optimize implant longevity and patient quality of life.

2025-09-01·BONE

Comparative effectiveness of romosozumab versus teriparatide for fracture prevention: A new-user, active comparator design

Article

作者: Ikenoue, Tatsuyoshi ; Okuda, Tadahisa ; Kurita, Noriaki ; Niihata, Kakuya ; Shimizu, Sayaka ; Tominaga, Ryoji ; Aita, Tetsuro ; Taguri, Masataka ; Ishii, Ryosuke

BACKGROUND:

Comparative evidence on the effectiveness of romosozumab and teriparatide in preventing osteoporotic fractures remains limited. This study evaluated their effectiveness in fracture prevention.

METHODS:

This observational new-user cohort study used the DeSC Healthcare database, a nationwide claims database in Japan. Patients aged ≥40 years with osteoporosis, defined by International Classification of Diseases, 10th Revision codes or prior fragility fractures, who newly initiated romosozumab or teriparatide between March 2019 and August 2021 were included. The primary outcome was the major osteoporotic fractures within 1 year. Secondary outcomes included 2-years fracture incidence and individual fracture types. Cox proportional hazards models, weighted by inverse probability-of-treatment derived from propensity scores, were used to estimate hazard ratios (HRs) with 95 % confidence intervals (CIs), accounting for patient- and facility-level confounders.

RESULTS:

Among 35,547 observations (romosozumab: 9603; teriparatide: 25,944), the mean ages were 80.3 and 80.0 years, 85.2 % and 81.3 % were women, and 64.4 % and 71.9 % had a history of fragility fracture, respectively. The 1-year incidences of major osteoporotic fractures were 10.14 per 100 person-years (teriparatide) and 7.01 per 100 person-years (romosozumab) (HR: 0.80, 95 % CI: 0.71, 0.89). Romosozumab was also associated with lower rates of composite fractures over 2 years (HR: 0.81, 95 % CI: 0.72, 0.90); vertebral fractures over 1 and 2 years; and proximal humeral, distal forearm, and proximal femoral fractures over 1 year.

CONCLUSIONS:

In this nationwide Japanese cohort, romosozumab use was associated with a lower incidence of major osteoporotic fractures compared to teriparatide over both 1- and 2-year follow-up periods among high-risk patients with osteoporosis.

2025-09-01·Oral Surgery Oral Medicine Oral Pathology Oral Radiology

Teriparatide as an adjuvant therapy in the management of advanced-stage medication-related osteonecrosis of the jaw

Article

作者: Chung, Kevin ; Yom, SaeHee K ; Huryn, Joseph M ; Estilo, Cherry L ; Singh, Annu ; Farooki, Azeez

Teriparatide, recombinant human parathyroid hormone, is a US Food and Drug Administration (FDA)-approved drug used for the treatment of osteoporosis in men and postmenopausal women. Recent studies have shown that it may promote bone healing in medication-related osteonecrosis of the jaw (MRONJ). We describe a case of successful management of advanced-stage MRONJ with teriparatide therapy that was initially prescribed for osteoporosis. This case demonstrates that in patients with progressive MRONJ with significant pain and frequent flares of acute infection, teriparatide may be a viable adjunct in treating MRONJ, as well as helping alleviate symptoms and improve quality of life. (Oral Surg Oral Med Oral Pathol Oral Radiol YEAR;VOL:page range).

100 项与特立帕肽（圣诺生物）相关的药物交易

登录后查看更多信息